Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology.

Saijo N.

Yonsei Med J. 2013 Jan 1;54(1):1-14. doi: 10.3349/ymj.2013.54.1.1. Review.

2.

Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach.

Mack PC, Gandara DR, Lara PN Jr.

Expert Rev Anticancer Ther. 2012 Dec;12(12):1591-6. doi: 10.1586/era.12.135. Review.

PMID:
23253224
3.

Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).

Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, Ichinose Y, Katakami N, Yamamoto N, Kudoh S, Sasaki J, Matsui K, Takayama K, Kashii T, Iwamoto Y, Sawa T, Okamoto I, Kurata T, Nakagawa K, Fukuoka M.

J Clin Oncol. 2010 Feb 10;28(5):753-60. doi: 10.1200/JCO.2009.23.3445. Epub 2009 Dec 28.

PMID:
20038730
4.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
5.

Overview of gefitinib in non-small cell lung cancer: an Asian perspective.

Jiang H.

Jpn J Clin Oncol. 2009 Mar;39(3):137-50. doi: 10.1093/jjco/hyn139. Epub 2008 Dec 16. Review.

PMID:
19088154
6.

Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).

Akamatsu H, Inoue A, Mitsudomi T, Kobayashi K, Nakagawa K, Mori K, Nukiwa T, Nakanishi Y, Yamamoto N.

Jpn J Clin Oncol. 2013 Jun;43(6):664-8. doi: 10.1093/jjco/hyt049. Epub 2013 Apr 12.

PMID:
23585689
7.

The role of gefitinib in the management of Asian patients with non-small cell lung cancer.

Chang AY.

Expert Opin Investig Drugs. 2008 Mar;17(3):401-11. doi: 10.1517/13543784.17.3.401 . Review. Erratum in: Expert Opin Investig Drugs. 2008 May;17(5):825.

PMID:
18321238
8.

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC).

Kobayashi K, Hagiwara K.

Target Oncol. 2013 Mar;8(1):27-33. doi: 10.1007/s11523-013-0258-9. Epub 2013 Jan 30. Review.

9.

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J.

J Clin Oncol. 2009 Jun 1;27(16):2653-9. doi: 10.1200/JCO.2008.17.3930. Epub 2009 May 4.

PMID:
19414683
10.

EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.

Yang CH.

Lung Cancer. 2008 Jun;60 Suppl 2:S23-30. doi: 10.1016/S0169-5002(08)70102-8. Review.

PMID:
18513581
11.

Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.

Kawano Y, Ohyanagi F, Yanagitani N, Kudo K, Horiike A, Tanimoto A, Nishizawa H, Ichikawa A, Sakatani T, Nakatomi K, Hagiwara S, Ninomiya H, Motoi N, Ishikawa Y, Horai T, Nishio M.

Anticancer Res. 2013 Aug;33(8):3327-33. Erratum in: Anticancer Res. 2013 Sep;33(9):4137.

PMID:
23898099
12.

Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.

Calvo E, Baselga J.

J Clin Oncol. 2006 May 10;24(14):2158-63. Review.

PMID:
16682734
13.

The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.

Sgambato A, Casaluce F, Maione P, Rossi A, Rossi E, Napolitano A, Palazzolo G, Bareschino MA, Schettino C, Sacco PC, Ciadiello F, Gridelli C.

Curr Med Chem. 2012;19(20):3337-52. Review.

PMID:
22664249
14.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.

Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR.

Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12. Review.

15.

Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.

Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH, Gandara DR.

Clin Lung Cancer. 2006 May;7(6):385-8. Review.

PMID:
16800963
16.

Implementation of modern therapy approaches and research for non-small cell lung cancer in Japan.

Nakanishi Y.

Respirology. 2015 Feb;20(2):199-208. doi: 10.1111/resp.12460. Review.

17.

[Molecular targeted therapy--non-small-cell lung cancer and gefitinib].

Shimizu J, Horio Y, Mitsudomi T.

Gan To Kagaku Ryoho. 2005 Nov;32(12):1879-85. Review. Japanese.

PMID:
16282720
18.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

PMID:
21670455
19.

Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.

de Marinis F, Rossi A, Di Maio M, Ricciardi S, Gridelli C; Italian Association of Thoracic Oncology.

Lung Cancer. 2011 Jul;73(1):1-10. doi: 10.1016/j.lungcan.2011.02.022. Epub 2011 Mar 25.

PMID:
21440325
20.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group.

N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.

Supplemental Content

Support Center